At AWS re:Invent, Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that LG AI Research, the artificial intelligence (...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical...
Perceptive eClinical, part of Perceptive Group, is pleased to announce the launch of ClinPhone 5, a ground-breaking new Randomization and Trial Supply Mana...
Professor Narayanan Parameswaran's team at the Department of Physiology at Michigan State University announced the results of a study that s...
Alteogen Inc. (KOSDAQ:196170) announced that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms o...
GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therape...
INCHEON, South Korea, Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced a contra...
SHANGHAI and HONG KONG, Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmac...
The Innovation Hub located in Songdo, Incheon will encompass a manufacturing facility together with a customer experience lab. Operations of the manufac...
GC Cell, a leading innovator in cell therapy, has officially announced the execution of a landmark 'Technology Transfer and License Agreement' with PT Bi...
Danaher Korea and the Korea Green Foundation have signed a Memorandum of Understanding (MOU) to jointly develop urban forests and implement a collaborati...
GC Cell Corporation (hereinafter referred to as "GC Cell"; 144510:KOSDAQ) and Lukas Biomedical Co., Ltd. (hereinafter referred to as "Lukas," TWSE ...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell thera...
© 2025 Biopharma Boardroom. All Rights Reserved.
